Bisphosphonate-associated osteonecrosis of the jaw

A review of 35 cases and an evaluation of its frequency in multiple myeloma patients

Samantha Pozzi, Raffaella Marcheselli, Stefano Sacchi, Luca Baldini, Francesco Angrilli, Elsa Pennese, Giovanni Quarta, Caterina Stelitano, Giuseppe Caparotti, Stefano Luminari, Pellegrino Musto, Donato Natale, Chiara Broglia, Angela Cuoghi, Daniele Dini, Paolo Di Tonno, Giovanna Leonardi, Graziano Pianezze, Vincenzo Pitini, Giuseppe Polimeno & 5 others Luisa Ponchio, Luciano Masini, Maurizio Musso, Mauro Spriano, Giuseppe Pollastri

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Over a period of 28 months, we observed five cases of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates (BP) at our institution. This prompted us to undertake a retrospective, multicenter study to analyse the characteristics of patients who exhibited ONJ and to define the frequency of ONJ in multiple myeloma (MM). We identified 35 cases in Gruppo Italiano Studio Linfomi centers during the period 2002-05. The median time from cancer diagnosis to the clinical onset of ONJ was 70 months. In these 35 cases of ONJ, 24 appeared 20-60 months after starting BP treatment. The time for the onset of ONJ was significantly shorter for patients treated with zoledronic acid alone than for those treated with pamidronate followed by zoledronic acid. The frequency of ONJ in the MM group during the study period was 1.9%, although the nature of the present study may have resulted in an underestimation of ONJ cases. Our analysis strongly suggested an association between the use of BP and the occurrence of ONJ, although we were unable to identify any definite risk factors with a retrospective study. The most frequently ONJ-associated clinical characteristics were chemotherapy treatment, steroid treatment, advanced age, female sex, anemia, parodonthopaties/dental procedures and thalidomide (in the case of MM patients).

Original languageEnglish
Pages (from-to)56-64
Number of pages9
JournalLeukemia and Lymphoma
Volume48
Issue number1
DOIs
Publication statusPublished - Jan 2007

Fingerprint

Bisphosphonate-Associated Osteonecrosis of the Jaw
Osteonecrosis
Jaw
Multiple Myeloma
zoledronic acid
pamidronate
Diphosphonates
Jaw Neoplasms
Retrospective Studies
Thalidomide
Multicenter Studies
Anemia
Tooth
Therapeutics
Steroids

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Bisphosphonate-associated osteonecrosis of the jaw : A review of 35 cases and an evaluation of its frequency in multiple myeloma patients. / Pozzi, Samantha; Marcheselli, Raffaella; Sacchi, Stefano; Baldini, Luca; Angrilli, Francesco; Pennese, Elsa; Quarta, Giovanni; Stelitano, Caterina; Caparotti, Giuseppe; Luminari, Stefano; Musto, Pellegrino; Natale, Donato; Broglia, Chiara; Cuoghi, Angela; Dini, Daniele; Tonno, Paolo Di; Leonardi, Giovanna; Pianezze, Graziano; Pitini, Vincenzo; Polimeno, Giuseppe; Ponchio, Luisa; Masini, Luciano; Musso, Maurizio; Spriano, Mauro; Pollastri, Giuseppe.

In: Leukemia and Lymphoma, Vol. 48, No. 1, 01.2007, p. 56-64.

Research output: Contribution to journalArticle

Pozzi, S, Marcheselli, R, Sacchi, S, Baldini, L, Angrilli, F, Pennese, E, Quarta, G, Stelitano, C, Caparotti, G, Luminari, S, Musto, P, Natale, D, Broglia, C, Cuoghi, A, Dini, D, Tonno, PD, Leonardi, G, Pianezze, G, Pitini, V, Polimeno, G, Ponchio, L, Masini, L, Musso, M, Spriano, M & Pollastri, G 2007, 'Bisphosphonate-associated osteonecrosis of the jaw: A review of 35 cases and an evaluation of its frequency in multiple myeloma patients', Leukemia and Lymphoma, vol. 48, no. 1, pp. 56-64. https://doi.org/10.1080/10428190600977690
Pozzi, Samantha ; Marcheselli, Raffaella ; Sacchi, Stefano ; Baldini, Luca ; Angrilli, Francesco ; Pennese, Elsa ; Quarta, Giovanni ; Stelitano, Caterina ; Caparotti, Giuseppe ; Luminari, Stefano ; Musto, Pellegrino ; Natale, Donato ; Broglia, Chiara ; Cuoghi, Angela ; Dini, Daniele ; Tonno, Paolo Di ; Leonardi, Giovanna ; Pianezze, Graziano ; Pitini, Vincenzo ; Polimeno, Giuseppe ; Ponchio, Luisa ; Masini, Luciano ; Musso, Maurizio ; Spriano, Mauro ; Pollastri, Giuseppe. / Bisphosphonate-associated osteonecrosis of the jaw : A review of 35 cases and an evaluation of its frequency in multiple myeloma patients. In: Leukemia and Lymphoma. 2007 ; Vol. 48, No. 1. pp. 56-64.
@article{fb3123ffcf2d49188fef3f6a2bdfd03b,
title = "Bisphosphonate-associated osteonecrosis of the jaw: A review of 35 cases and an evaluation of its frequency in multiple myeloma patients",
abstract = "Over a period of 28 months, we observed five cases of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates (BP) at our institution. This prompted us to undertake a retrospective, multicenter study to analyse the characteristics of patients who exhibited ONJ and to define the frequency of ONJ in multiple myeloma (MM). We identified 35 cases in Gruppo Italiano Studio Linfomi centers during the period 2002-05. The median time from cancer diagnosis to the clinical onset of ONJ was 70 months. In these 35 cases of ONJ, 24 appeared 20-60 months after starting BP treatment. The time for the onset of ONJ was significantly shorter for patients treated with zoledronic acid alone than for those treated with pamidronate followed by zoledronic acid. The frequency of ONJ in the MM group during the study period was 1.9{\%}, although the nature of the present study may have resulted in an underestimation of ONJ cases. Our analysis strongly suggested an association between the use of BP and the occurrence of ONJ, although we were unable to identify any definite risk factors with a retrospective study. The most frequently ONJ-associated clinical characteristics were chemotherapy treatment, steroid treatment, advanced age, female sex, anemia, parodonthopaties/dental procedures and thalidomide (in the case of MM patients).",
author = "Samantha Pozzi and Raffaella Marcheselli and Stefano Sacchi and Luca Baldini and Francesco Angrilli and Elsa Pennese and Giovanni Quarta and Caterina Stelitano and Giuseppe Caparotti and Stefano Luminari and Pellegrino Musto and Donato Natale and Chiara Broglia and Angela Cuoghi and Daniele Dini and Tonno, {Paolo Di} and Giovanna Leonardi and Graziano Pianezze and Vincenzo Pitini and Giuseppe Polimeno and Luisa Ponchio and Luciano Masini and Maurizio Musso and Mauro Spriano and Giuseppe Pollastri",
year = "2007",
month = "1",
doi = "10.1080/10428190600977690",
language = "English",
volume = "48",
pages = "56--64",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Bisphosphonate-associated osteonecrosis of the jaw

T2 - A review of 35 cases and an evaluation of its frequency in multiple myeloma patients

AU - Pozzi, Samantha

AU - Marcheselli, Raffaella

AU - Sacchi, Stefano

AU - Baldini, Luca

AU - Angrilli, Francesco

AU - Pennese, Elsa

AU - Quarta, Giovanni

AU - Stelitano, Caterina

AU - Caparotti, Giuseppe

AU - Luminari, Stefano

AU - Musto, Pellegrino

AU - Natale, Donato

AU - Broglia, Chiara

AU - Cuoghi, Angela

AU - Dini, Daniele

AU - Tonno, Paolo Di

AU - Leonardi, Giovanna

AU - Pianezze, Graziano

AU - Pitini, Vincenzo

AU - Polimeno, Giuseppe

AU - Ponchio, Luisa

AU - Masini, Luciano

AU - Musso, Maurizio

AU - Spriano, Mauro

AU - Pollastri, Giuseppe

PY - 2007/1

Y1 - 2007/1

N2 - Over a period of 28 months, we observed five cases of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates (BP) at our institution. This prompted us to undertake a retrospective, multicenter study to analyse the characteristics of patients who exhibited ONJ and to define the frequency of ONJ in multiple myeloma (MM). We identified 35 cases in Gruppo Italiano Studio Linfomi centers during the period 2002-05. The median time from cancer diagnosis to the clinical onset of ONJ was 70 months. In these 35 cases of ONJ, 24 appeared 20-60 months after starting BP treatment. The time for the onset of ONJ was significantly shorter for patients treated with zoledronic acid alone than for those treated with pamidronate followed by zoledronic acid. The frequency of ONJ in the MM group during the study period was 1.9%, although the nature of the present study may have resulted in an underestimation of ONJ cases. Our analysis strongly suggested an association between the use of BP and the occurrence of ONJ, although we were unable to identify any definite risk factors with a retrospective study. The most frequently ONJ-associated clinical characteristics were chemotherapy treatment, steroid treatment, advanced age, female sex, anemia, parodonthopaties/dental procedures and thalidomide (in the case of MM patients).

AB - Over a period of 28 months, we observed five cases of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates (BP) at our institution. This prompted us to undertake a retrospective, multicenter study to analyse the characteristics of patients who exhibited ONJ and to define the frequency of ONJ in multiple myeloma (MM). We identified 35 cases in Gruppo Italiano Studio Linfomi centers during the period 2002-05. The median time from cancer diagnosis to the clinical onset of ONJ was 70 months. In these 35 cases of ONJ, 24 appeared 20-60 months after starting BP treatment. The time for the onset of ONJ was significantly shorter for patients treated with zoledronic acid alone than for those treated with pamidronate followed by zoledronic acid. The frequency of ONJ in the MM group during the study period was 1.9%, although the nature of the present study may have resulted in an underestimation of ONJ cases. Our analysis strongly suggested an association between the use of BP and the occurrence of ONJ, although we were unable to identify any definite risk factors with a retrospective study. The most frequently ONJ-associated clinical characteristics were chemotherapy treatment, steroid treatment, advanced age, female sex, anemia, parodonthopaties/dental procedures and thalidomide (in the case of MM patients).

UR - http://www.scopus.com/inward/record.url?scp=34247218044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247218044&partnerID=8YFLogxK

U2 - 10.1080/10428190600977690

DO - 10.1080/10428190600977690

M3 - Article

VL - 48

SP - 56

EP - 64

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -